Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 1;56(suppl_5):v12-v16.
doi: 10.1093/rheumatology/kex198.

Points to consider when doing a trial primarily involving the heart

Yannick Allanore  1 , Oliver Distler  2 , Ulrich A Walker  3 , Dinesh Khanna  4 , Daniel E Furst  5 , Christophe Meune  6
Affiliations
Review

Points to consider when doing a trial primarily involving the heart

Yannick Allanore et al. Rheumatology (Oxford). .

Abstract

Cardiac involvement contributes to the severity of SSc and should carefully be investigated and managed in SSc patients. Although it is commonly sub-clinical, once symptomatic it has a poor prognosis. Several complementary tools (circulating biomarkers, electrocardiography, echocardiography, scintigraphy or MRI) allow the assessment of all the various cardiac structures (endocardium, myocardium and pericardium) and heart function. Treatment remains empirical but cardiac trials in SSc can add data to the treatment of this complication.

Keywords: arrhythmia; cardiac fibrosis; heart; heart failure; myocarditis; pericarditis; systemic sclerosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Systemic sclerosis: state of the art on clinical practice guidelines.
    Smith V, Scirè CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, Matucci-Cerinic M. Smith V, et al. RMD Open. 2018 Oct 18;4(Suppl 1):e000782. doi: 10.1136/rmdopen-2018-000782. eCollection 2018. RMD Open. 2018. PMID: 30402270 Free PMC article.
  • Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT.
    Treutlein C, Distler JHW, Tascilar K, Fakhouri SC, Györfi AH, Atzinger A, Matei AE, Dees C, Büttner-Herold M, Kuwert T, Prante O, Bäuerle T, Uder M, Schett G, Schmidkonz C, Bergmann C. Treutlein C, et al. Eur J Nucl Med Mol Imaging. 2023 May;50(6):1629-1635. doi: 10.1007/s00259-022-06081-4. Epub 2022 Dec 16. Eur J Nucl Med Mol Imaging. 2023. PMID: 36522438 Free PMC article.

References

    1. Steen VD, Medsger TA Jr.. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437–44. - PubMed
    1. Perera A, Fertig N, Lucas M. et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007;56:2740–6. - PubMed
    1. Ferri C, Valentini G, Cozzi F. et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002;81:139–53. - PubMed
    1. Scussel-Lonzetti L, Joyal F, Raynauld JP. et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002;81:154–67. - PubMed
    1. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB. et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2–10. - PubMed

Publication types

MeSH terms